X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with THOMAS COOK INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs THOMAS COOK INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

THOMAS COOK INDIA 
   Change

Thomas Cook India (TCIL) offers a broad spectrum of leisure travel related services such as package tours, currency exchange and travel insurance as well as hotel and flight reservations. TCIL has been present in India for 128 years. In 2006, the com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES THOMAS COOK INDIA INDOCO REMEDIES/
THOMAS COOK INDIA
 
P/E (TTM) x 86.5 45.2 191.4% View Chart
P/BV x 3.1 1.0 324.9% View Chart
Dividend Yield % 0.7 0.2 429.1%  

Financials

 INDOCO REMEDIES   THOMAS COOK INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
THOMAS COOK INDIA
Mar-18
INDOCO REMEDIES/
THOMAS COOK INDIA
5-Yr Chart
Click to enlarge
High Rs360292 123.5%   
Low Rs249202 123.3%   
Sales per share (Unadj.) Rs119.0303.8 39.2%  
Earnings per share (Unadj.) Rs8.4165.6 5.0%  
Cash flow per share (Unadj.) Rs15.2169.3 9.0%  
Dividends per share (Unadj.) Rs1.600.38 421.1%  
Dividend yield (eoy) %0.50.2 341.3%  
Book value per share (Unadj.) Rs70.7234.2 30.2%  
Shares outstanding (eoy) m92.15370.21 24.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.8 315.0%   
Avg P/E ratio x36.41.5 2,443.3%  
P/CF ratio (eoy) x20.01.5 1,371.6%  
Price / Book Value ratio x4.31.1 408.7%  
Dividend payout %19.10.2 8,337.9%   
Avg Mkt Cap Rs m28,08391,442 30.7%   
No. of employees `0006.02.4 249.2%   
Total wages/salary Rs m2,16753,022 4.1%   
Avg. sales/employee Rs Th1,817.046,442.4 3.9%   
Avg. wages/employee Rs Th359.021,891.9 1.6%   
Avg. net profit/employee Rs Th127.725,315.4 0.5%   
INCOME DATA
Net Sales Rs m10,968112,483 9.8%  
Other income Rs m401,338 3.0%   
Total revenues Rs m11,007113,822 9.7%   
Gross profit Rs m1,5654,005 39.1%  
Depreciation Rs m6331,367 46.3%   
Interest Rs m621,490 4.2%   
Profit before tax Rs m9092,487 36.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0167 0.0%   
Extraordinary Inc (Exp) Rs m058,255 0.0%   
Tax Rs m139-406 -34.2%   
Profit after tax Rs m77161,314 1.3%  
Gross profit margin %14.33.6 400.6%  
Effective tax rate %15.3-16.3 -93.5%   
Net profit margin %7.054.5 12.9%  
BALANCE SHEET DATA
Current assets Rs m5,72528,926 19.8%   
Current liabilities Rs m5,45428,153 19.4%   
Net working cap to sales %2.50.7 359.2%  
Current ratio x1.01.0 102.2%  
Inventory Days Days620 175,902.4%  
Debtors Days Days7228 258.0%  
Net fixed assets Rs m5,30717,362 30.6%   
Share capital Rs m184370 49.8%   
"Free" reserves Rs m6,33186,339 7.3%   
Net worth Rs m6,51686,709 7.5%   
Long term debt Rs m1,3232,310 57.3%   
Total assets Rs m11,970122,042 9.8%  
Interest coverage x15.62.7 586.2%   
Debt to equity ratio x0.20 762.3%  
Sales to assets ratio x0.90.9 99.4%   
Return on assets %7.051.5 13.5%  
Return on equity %11.870.7 16.7%  
Return on capital %12.470.1 17.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,507388 1,160.4%   
Fx outflow Rs m1,141139 824.1%   
Net fx Rs m3,366250 1,346.7%   
CASH FLOW
From Operations Rs m886-2,442 -36.3%  
From Investments Rs m-1,706-999 170.7%  
From Financial Activity Rs m1,3164,767 27.6%  
Net Cashflow Rs m497-2,254 -22.0%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 0.2 6,250.0%  
FIIs % 6.0 12.4 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 12.4 180.6%  
Shareholders   12,805 34,019 37.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   STC INDIA  TVS SRICHAKRA  EDELWEISS FINANCIAL  RELIGARE ENT.  CHOLAMANDALAM INVEST.  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 139.4% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, INDOCO REMEDIES has posted a net profit of Rs 78 m (down 139.4% YoY). Sales on the other hand came in at Rs 2 bn (down 17.3% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

THOMAS COOK INDIA Announces Quarterly Results (2QFY19); Net Profit Down 119.7% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, THOMAS COOK INDIA has posted a net profit of Rs 146 m (down 119.7% YoY). Sales on the other hand came in at Rs 16 bn (down 40.2% YoY). Read on for a complete analysis of THOMAS COOK INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Dec 11, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS